New England Journal of Medicine · 1976 · 251 citations · 27 references
MedicineEndocrinologyPharmacologyDiabetologyMetabolic RegulationPediatric EndocrinologyDiabetes ManagementDiabetes MellitusGlucagon TherapyGlucose HomeostasisGlycemic ControlInsulin TherapyBlood Glucose RegulationDiabetic ComplicationsGlucagon TreatmentInsulin ActionInsulin Deficiency MechanismsInsulin ResponseInsulin-like Growth Factor DeficiencyInsulin-regulated Glucose Metabolism
Glucagon was infused to maintain plasma concentrations three to six times the basal level (300 to 600 pg per milliliter) into 16 normal and seven non-diabetic obese subjects. Hyperglucagonemia caused only a transient rise of 5 to 10 mg per 100 ml in basal glucose levels and had no effect on oral glucose tolerance or plasma insulin. In three patients with adult and two with juvenile-onset diabetes on maintenance insulin, hyperglucagonemia maintained for two to four days caused no change in plasma glucose of ketone concentration. In contrast, in nine insulin-withdrawn patients the glycemic response to hyperglucagonemia was five to 15 times greater (P less then 0.05) than in normal controls. Hyperglucagonemia does not cause glucose intolerance in normal subjects or bring about deterioration of diabetic control when insulin is available. Glucagon in the insulin-deprived patient can worsen the diabetic state. These findings suggest the primary role of insulin deficiency in the diabetogenic action of glucagon.
27
Abnormal Alpha-Cell Function in Diabetes
Walter A. Müller, Gerald R. Faloona, E Aguilar-Parada et al. · New England Journal of Medicine · 1970 · 626 citations
Medicine, Endocrinology, Physiology +14
Somatostatin: Hypothalamic Inhibitor of the Endocrine Pancreas
Donna J. Koerker, Willy Ruch, Elliott W. Chideckel et al. · Science · 1974 · 523 citations
Prevention of Human Diabetic Ketoacidosis by Somatostatin
John E. Gerich, Mara Lorenzi, Dennis M. Bier et al. · New England Journal of Medicine · 1975 · 356 citations